<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with endemic Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who failed primary treatment with the Malawi 2002 or 2003 Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treatment protocols, consisting of high frequency <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 40 mg/kg and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, were offered rescue chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-eight patients (14 boys and 14 girls; age range 3-13 years) with resistant disease (n=8) or relapse (n=20) presented to the Queen Elizabeth Central Hospital, Blantyre, Malawi </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment consisted of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 60 mg/kg and <z:chebi fb="0" ids="28445">vincristine</z:chebi> 1.5 mg/m(2) i.v. on Days 1, 8 and 15, plus intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> on the same days in those patients treated for a relapse </plain></SENT>
<SENT sid="3" pm="."><plain>The majority of patients (81%) had St Jude stage III or IV disease </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty patients (71%) achieved a complete clinical remission </plain></SENT>
<SENT sid="5" pm="."><plain>Day 8 treatment was delayed in eight children and Day 15 treatment in five patients, both for a median of 7 days, mainly due to <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Ten patients relapsed after 42-311 days (median 105 days) </plain></SENT>
<SENT sid="7" pm="."><plain>Ten patients (36%) remained in remission for 353-712 days (median 487 days) </plain></SENT>
<SENT sid="8" pm="."><plain>Patients whose first relapse occurred after 6 months as well as those with limited disease had the best outcome </plain></SENT>
<SENT sid="9" pm="."><plain>This simple 15-day chemotherapy schedule salvaged 36% of patients and significantly increased the overall cure rate of our Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
</text></document>